7 Stocks on Jim Cramer’s Radar

2. Eli Lilly and Company (NYSE:LLY)

Number of Hedge Fund Holders: 106

Cramer mentioned one of the leading global pharmaceutical companies, Eli Lilly and Company (NYSE:LLY), during the Mad Money episode and said:

“Okay, the problem with Eli Lilly is people are saying, you know what, after a year, people are no longer taking the drugs, they’re going off it, a huge percentage’s going off it. I think that you own this thing because it’s about cardiac… It’s about high blood pressure. It’s about dementia, may even be about cancer, not just about weight and diabetes. So I think you hold on to Eli Lilly. We continue to hold it for the trust. I do think there’ll be good numbers, but that last quarter wasn’t good. I totally understand the trepidation about the stock, but I still like it.”

Toward the mid of January, Cramer discussed Eli Lilly’s (NYSE:LLY) stock drop, noting that the company had projected $58 to $61 billion in revenue for the coming year, driven by its GLP-1 drugs for diabetes, weight loss, and obstructive sleep apnea. However, its fourth-quarter results fell short of Wall Street’s expectations. Despite this, Cramer saw the drop as a buying opportunity, particularly due to Mounjaro’s potential in treating a wide range of conditions.

He acknowledged challenges with the drug’s launch but remains optimistic about its long-term prospects. Cramer also highlighted political factors affecting the company, including criticism of GLP-1 drugs from Robert Kennedy Jr. Despite some short-term concerns, he believes in Eli Lilly’s (NYSE:LLY) future potential and recommended buying the stock.